Optimizing Advanced Therapies in Ulcerative Colitis: Is Your Practice Up to Date?A Focus on Clinical Evidence and Guideline Recommendations
Approach to the management of recently diagnosed inflammatory bowel disease patients: a user's guide for adult and pediatric gastroenterologists.
Agrawal M, et al. Gastroenterology. 2021;161(1):47-65.
STRIDE-II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD.
Turner D, et al. Gastroenterology. 2021;160(5):1570-1583.
Ungaro R, et al. Am J Gastroenterol. 2019;114(6):874-883.
Mumolo MG, et al. World J Gastroenterol. 2018;24(33):3681-3694.
Sands BE, et al. N Engl J Med. 2019; 381(13):1215-1226.
Comparison of real-world treatment outcomes with vedolizumab versus infliximab in biologic-naive patients with inflammatory bowel disease.
Patel H, et al. Crohn's Colitis 360. 2019;1(2):otz022.
Prediction of outcome of treatment of acute severe ulcerative colitis using principal component analysis and artificial intelligence.
Ghoshal UC, et al. JGH Open. 2020;4(5):889-897.
P025 Ozanimod efficacy, safety, and histology in patients with moderate-to-severe ulcerative colitis during induction in the phase 3 True North study.
Sandborn W, et al. Am J Gastroenterol. 2020;115(suppl 1):S6-S7.
FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions.
US Food and Drug Administration. 2021.
Colombel JF, et al. Gut. 2017;66(5):839-851.
Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis of results from phase 2/3 studies.
Sandborn WJ, et al. Inflamm Bowel Dis. 2021;27(7):994-1007.
Theede K, et al. Expert Rev Clin Immunol. 2017;13(7):645-647.
Is Your Practice Up to Date? A Focus on Clinical Evidence and Guideline Recommendations
Improved Diagnostic and Management Strategies
Long-Term Management Strategies to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Evolving Strategies for Diagnosis and Long-Term Management
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
Targeting Immune Dysregulation and Delivering Comprehensive Care
Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Got it? Treat it!
Looking Beyond Barriers to Optimize Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
Using Imaging to Improve Patient Outcomes
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
The Emerging Role of the Diabetologist
Key Issues Impacting OB/GYN Practice
Translating Pathophysiology into Targeted Treatments
Think You Know JAK?
An Interactive Experience Highlighting Recent Clinical Advances
Hot Topics in HBV, HCV, and NASH
Emerging Concepts in Patient Management
Building Your Understanding to Combat a Growing Problem
Debates & Discussions on the Evolving Role of JAK Inhibitors
Why It Matters in OB/GYN Practice Today
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
The Evolving Role of JAK Inhibitors
Understanding the Growing Syndemic — Opioids, HCV, and HIV
Unpacking the Evidence for Their Use Today and Tomorrow
Appraising the Therapeutic Armamentarium in Moderate and Severe Disease
The PCP’s Role in HCV Elimination
Unlocking Novel Paths to Patient Care
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
The Increasing Role of JAK Inhibitors
An Interactive Learning Experience
Unlocking Novel Paths to Patient Care
New Pathways to Patient Management
A Multidisciplinary Online Mini-Curriculum
Volume 1: A Guided Tour of the Evidence Driving Selection of First-line Advanced Therapies in Moderate to Severe IBD
New Avenues to the Management of Severe Asthma
Establishing Clinical Readiness Through Mentored Learning
Interdisciplinary Strategies for Adult and Pediatric Patients